FDA approves drug for sexual desires disorders in women
On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.…




*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.